Invasive Candida auris infections in Kuwait hospitals: epidemiology, antifungal treatment and outcome

Affiliations

01 October 2018

-

doi: 10.1007/s15010-018-1164-y


Abstract

Purpose: Candida auris is a recently recognized yeast pathogen, which has attracted worldwide attention due to its multidrug-resistant nature and associated high mortality rates. Its persistence in hospital environment and propensity of nosocomial transmission underscores the need of continuous monitoring to prevent outbreaks. Since the first case of C. auris candidemia in May, 2014, we have identified 17 additional invasive cases, which are described here.

Methods: Identity of 17 isolates originating from proven or possible cases of invasive C. auris infection and identified as Candida haemulonii by Vitek 2 yeast identification system was confirmed by PCR-sequencing of rDNA. Information about risk factors, treatment and outcomes were retrospectively retrieved from case files. Antifungal susceptibility testing was performed by Etest.

Results: Thirteen cases of candidemia and 4 cases of other invasive infections were detected in 6 hospitals across Kuwait. Major risk factors included adult patients with cancer, diabetes, gastrointestinal/liver diseases and extended (> 25 days) hospital stay. All isolates were resistant to fluconazole. Additionally, 5 and 4 isolates were also resistant to voriconazole and amphotericin B, respectively. Despite antifungal treatment, 9 of 15 patients died. Most patients (n = 12) were hospitalized in 2 hospitals that are in close proximity, whereas 5 other patients were from 3 hospitals that are situated > 10 km apart.

Conclusions: Occurrence of successive cases of invasive C. auris infections with resulting mortality in nine patients suggests persistence of this multidrug-resistant yeast in major hospitals in Kuwait. Early detection by continuous surveillance and enforcement of infection control measures are recommended.

Keywords: Antifungal susceptibility; Candida auris; Epidemiology; Invasive infections; Kuwait.


Similar articles

Increasing prevalence, molecular characterization and antifungal drug susceptibility of serial Candida auris isolates in Kuwait.

Khan Z, Ahmad S, Al-Sweih N, Joseph L, Alfouzan W, Asadzadeh M.PLoS One. 2018 Apr 9;13(4):e0195743. doi: 10.1371/journal.pone.0195743. eCollection 2018.PMID: 29630658 Free PMC article.

Candida auris in various hospitals across Kuwait and their susceptibility and molecular basis of resistance to antifungal drugs.

Ahmad S, Khan Z, Al-Sweih N, Alfouzan W, Joseph L.Mycoses. 2020 Jan;63(1):104-112. doi: 10.1111/myc.13022. Epub 2019 Nov 3.PMID: 31618799

Candida and candidaemia. Susceptibility and epidemiology.

Arendrup MC.Dan Med J. 2013 Nov;60(11):B4698.PMID: 24192246 Review.

First case of Candida auris infection in Belgium in a surgical patient from Kuwait.

Dewaele K, Frans J, Smismans A, Ho E, Tollens T, Lagrou K.Acta Clin Belg. 2020 Jun;75(3):221-228. doi: 10.1080/17843286.2018.1555114. Epub 2018 Dec 4.PMID: 30514182 Review.

Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method.

Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, Meis JF, Chowdhary A.J Clin Microbiol. 2015 Jun;53(6):1823-30. doi: 10.1128/JCM.00367-15. Epub 2015 Mar 25.PMID: 25809970 Free PMC article.


Cited by

First Report of Azole-Resistant Aspergillus fumigatus with TR46/Y121F/T289A Mutations in Kuwait and an Update on Their Occurrence in the Middle East.

Asadzadeh M, Alobaid K, Ahmad S, Mazloum S.J Fungi (Basel). 2023 Jul 25;9(8):784. doi: 10.3390/jof9080784.PMID: 37623555 Free PMC article.

Candida auris Blood stream infection- a descriptive study from Qatar.

Koleri J, Petkar HM, Rahman S Al Soub HA, Rahman S AlMaslamani MA.BMC Infect Dis. 2023 Aug 6;23(1):513. doi: 10.1186/s12879-023-08477-5.PMID: 37544995 Free PMC article.

Candida auris: outbreak fungal pathogen in COVID-19 pandemic: a systematic review and meta-analysis.

Bagheri Lankarani K, Akbari M, Tabrizi R, Vali M, Sekhavati E, Heydari ST, Khodadadi H, Ahmadizar F.Iran J Microbiol. 2022 Jun;14(3):276-284. doi: 10.18502/ijm.v14i3.9753.PMID: 37124855 Free PMC article. Review.

Strategies to Prevent Transmission of Candida auris in Healthcare Settings.

Ahmad S, Asadzadeh M.Curr Fungal Infect Rep. 2023;17(1):36-48. doi: 10.1007/s12281-023-00451-7. Epub 2023 Jan 26.PMID: 36718372 Free PMC article. Review.

Investigation of Novel Quinoline-Thiazole Derivatives as Antimicrobial Agents: In Vitro and In Silico Approaches.

Evren AE, Karaduman AB, Sağlik BN, Özkay Y, Yurttaş L.ACS Omega. 2022 Dec 29;8(1):1410-1429. doi: 10.1021/acsomega.2c06871. eCollection 2023 Jan 10.PMID: 36643421 Free PMC article.


KMEL References


References

  1.  
    1. Mycoses. 2008 Jul;51(4):318-23 - PubMed
  2.  
    1. Microbiol Immunol. 2009 Jan;53(1):41-4 - PubMed
  3.  
    1. J Antimicrob Chemother. 2017 Jun 1;72(6):1794-1801 - PubMed
  4.  
    1. Clin Microbiol Infect. 2016 Mar;22(3):277.e1-9 - PubMed
  5.  
    1. PLoS One. 2018 Apr 9;13(4):e0195743 - PubMed
  6.  
    1. Mycoses. 2018 Jan;61(1):44-47 - PubMed
  7.  
    1. Antimicrob Resist Infect Control. 2016 Oct 19;5:35 - PubMed
  8.  
    1. Antimicrob Agents Chemother. 2017 Apr 24;61(5): - PubMed
  9.  
    1. Euro Surveill. 2018 Mar;23(13): - PubMed
  10.  
    1. Intensive Care Med. 2015 Feb;41(2):285-95 - PubMed
  11.  
    1. Int J Infect Dis. 2018 May;70:36-37 - PubMed
  12.  
    1. Mycoses. 2018 Jul;61(7):498-505 - PubMed
  13.  
    1. Clin Infect Dis. 2009 Mar 15;48(6):e57-61 - PubMed
  14.  
    1. MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1234-1237 - PubMed
  15.  
    1. Antonie Van Leeuwenhoek. 2010 Mar;97(3):253-9 - PubMed
  16.  
    1. Emerg Infect Dis. 2013 Oct;19(10):1670-3 - PubMed
  17.  
    1. Indian J Med Microbiol. 2013 Jan-Mar;31(1):90-1 - PubMed
  18.  
    1. Mycoses. 2018 May 8;:null - PubMed
  19.  
    1. J Infect. 2017 Oct;75(4):373-376 - PubMed
  20.  
    1. Can Commun Dis Rep. 2017 Jul 06;43(7-8):150-153 - PubMed
  21.  
    1. Eur J Clin Microbiol Infect Dis. 2014 Jun;33(6):919-26 - PubMed
  22.  
    1. Emerg Infect Dis. 2015 Jun;21(6):1091-2 - PubMed
  23.  
    1. J Infect. 2016 Oct;73(4):369-74 - PubMed
  24.  
    1. Emerg Infect Dis. 2017 Jan;23(1):162-164 - PubMed
  25.  
    1. J Clin Microbiol. 2011 Sep;49(9):3139-42 - PubMed
  26.  
    1. Mycoses. 2017 Aug;60(8):488-492 - PubMed
  27.  
    1. J Clin Microbiol. 2015 Jun;53(6):1823-30 - PubMed
  28.  
    1. Mycoses. 2017 Sep;60(9):569-575 - PubMed
  29.  
    1. Clin Infect Dis. 2017 Jan 15;64(2):134-140 - PubMed
  30.  
    1. Emerg Infect Dis. 2017 Feb;23(1): - PubMed
  31.  
    1. Emerg Infect Dis. 2018 Apr;24(4):801-804 - PubMed
  32.  
    1. Antonie Van Leeuwenhoek. 2008 Oct;94(3):343-52 - PubMed
  33.  
    1. J Clin Microbiol. 2017 Oct;55(10):2996-3005 - PubMed
  34.  
    1. J Hosp Infect. 2016 Nov;94(3):209-212 - PubMed
  35.  
    1. PLoS Pathog. 2017 May 18;13(5):e1006290 - PubMed
  36.  
    1. Antimicrob Agents Chemother. 2017 May 24;61(6): - PubMed
  37.  
    1. Clin Microbiol Newsl. 2017 Jul 1;39(13):99-103 - PubMed
  38.  
    1. Emerg Infect Dis. 2014 Jul;20(7):1250-1 - PubMed
  39.  
    1. Mycopathologia. 2018 Jun;183(3):559-564 - PubMed